JERUSALEM & MIAMI--(BUSINESS WIRE)--Oct. 11, 2005--Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) and IVAX Corporation (AMEX:IVX) announced today that, as expected, each party has received a request for additional information (commonly referred to as a “second request”) from the U.S. Federal Trade Commission (FTC) in connection with Teva’s pending acquisition of IVAX. The parties have been working with the FTC staff since shortly after the announcement of the transaction and intend to respond promptly to the second request.
